Zhengye Biotechnology Receives NASDAQ Notice for Delayed 2024 Annual Report Filing
Zhengye Biotechnology Holding Ltd. has announced a delay in filing its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company received a delinquency letter from NASDAQ, notifying it of non-compliance with listing requirements due to this delay. Zhengye has 60 days to submit a compliance plan to regain compliance, potentially extending the deadline to November 11, 2025. The delayed filing currently has no immediate impact on the company's NASDAQ listing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-047332), on May 23, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。